ImmunoGen Inc IMGN announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine (pivekimab) in patients with frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive blood cancer.
Enrollment continues in the frontline CADENZA cohort; top-line data is expected in 2024.
In frontline-treated patients, including those with de novo and PCHM, the objective response rate (ORR) is 80% (24/30 patients) with a composite complete remission (CCR) rate of 73% (22/30 patients), and an additional patient achieving a CR post-transplant.
The median duration of response (DOR) for all responders in frontline-treated patients was 12.7 months.
In R/R patients, the ORR was 33% (16/49 patients), with a CCR rate of 20% (10/49 patients), including those who previously failed intensive chemotherapy and/or transplant.
The median DOR for all responders in R/R patients was 7.1 months.
Pivekimab continues to exhibit manageable safety; no new safety signals were observed.
Price Action: IMGN shares are up 7.71% at $16.97 on the last check Friday.
